Cargando…

Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial

OBJECTIVES: To characterize the blood pressure (BP) profile of the new β(3)-adrenergic receptor agonist, vibegron, in patients with overactive bladder. METHODS: Patients were randomized to once-daily vibegron 75 mg or placebo for 28 days and underwent ambulatory BP monitoring. The primary endpoint w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weber, Michael A., Haag-Molkenteller, Cornelia, King, Jennifer, Walker, Ann, Mudd, Paul N., White, William B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Devices and Technology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893125/ https://www.ncbi.nlm.nih.gov/pubmed/34699409 http://dx.doi.org/10.1097/MBP.0000000000000572

Ejemplares similares

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial
por: Lacy, Brian E., et al.
Publicado: (2022)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
por: Dmochowski, Roger R., et al.
Publicado: (2023)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Validation of Uright model TD 3127AT wireless-portable ambulatory blood pressure monitoring device with timer trigger modification, standard cuff size, in normotensive and mild hypertensive patients of Thailand registry (Thai valid ambulatory blood pressure monitoring)
por: Laosanguanek, Wanchat, et al.
Publicado: (2022)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Validation of the ABPMpro ambulatory blood pressure monitor in the general population according to AAMI/ESH/ISO Universal Standard (ISO 81060-2:2018)
por: Roth, Bernhard, et al.
Publicado: (2023)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

Blood pressure altering method affects correlation with pulse arrival time
por: Heimark, Sondre, et al.
Publicado: (2021)

Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement
por: Liu, Chengyu, et al.
Publicado: (2016)

Remote blood pressure monitoring with a wearable photoplethysmographic device in patients undergoing coronary angiography: the senbiosys substudy
por: Schukraft, Sara, et al.
Publicado: (2022)

Accurate blood pressure during patient arm movement: the Welch Allyn Connex Spot Monitor’s SureBP algorithm
por: Alpert, Bruce S., et al.
Publicado: (2019)

Validation of the Aktiia blood pressure cuff for clinical use according to the ANSI/AAMI/ISO 81060-2:2013 protocol
por: Alexandre, Jérémy, et al.
Publicado: (2023)

Validation of the Somnotouch-NIBP noninvasive continuous blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010
por: Bilo, Grzegorz, et al.
Publicado: (2015)

Smartphone based blood pressure measurement: accuracy of the OptiBP mobile application according to the AAMI/ESH/ISO universal validation protocol
por: Degott, Jean, et al.
Publicado: (2021)

Comparisons of automated blood pressures in a primary health care setting with self-measurements at the office and at home using the Omron i-C10 device
por: Al-Karkhi, Isam, et al.
Publicado: (2015)

Validation of the Welch Allyn Home blood pressure monitor with professional SureBP algorithm with a special feature of accuracy during involuntary (tremor) patient movement
por: Alpert, Bruce S.
Publicado: (2019)

Validation of the AViTA BPM636 upper arm blood pressure monitor in adults and pregnant women according to the ANSI/AAMI/ISO 81060-2:2013
por: Lee, Chien-Nan, et al.
Publicado: (2023)

Validation of the U60EH Wrist Electronic Blood Pressure Monitor in general population according to the ISO 81060-2:2018/AMD 1:2020 Protocol
por: Mu, Sicong, et al.
Publicado: (2023)

Validation of the JAMR F1701T (arm type) pressure monitor according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/ISO 81060-2:2018 protocol
por: Li, Jing, et al.
Publicado: (2023)

Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device
por: Vybornova, Anna, et al.
Publicado: (2021)

Validation of the JOYTECH DBP-6279B blood pressure monitor in adults and adolescents according to the AAMI/ESH/ISO universal standard(ISO 81060-2:2018 + Amd.1:2020)
por: Duan, Baojing, et al.
Publicado: (2023)

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

Smartphone application-supported validation of three automatic devices for self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010: the Omron HEM-7120, Yuwell YE680A and Cofoe KF-65B
por: Zhang, Puhong, et al.
Publicado: (2021)

Validation of the Omron HEM-7320-LA, upper arm blood pressure monitor with Intelli Wrap Technology Cuff HEM-FL1 for self-measurement and clinic use according to the European Society of Hypertension International Protocol revision 2010 in the Mexican population
por: Grover-Páez, Fernando, et al.
Publicado: (2017)

Medium-Term Effects of Septal and Apical Pacing in Pacemaker-Dependent Patients: A Double-Blind Prospective Randomized Study
por: Molina, Luis, et al.
Publicado: (2014)

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
por: Staskin, David, et al.
Publicado: (2023)

Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2020)

Validation of the Welch Allyn Pro BP 2000, a professional-grade inflation-based automated sphygmomanometer with arrhythmia detection in a combined pediatric and adult population by ANSI/AAMI/ISO standard testing
por: Alpert, Bruce S.
Publicado: (2018)

Validation of the STEP deflation algorithm of the Midmark IQvitals Zone Vital Signs Monitor: part of a novel clinical ecosystem
por: Alpert, Bruce S.
Publicado: (2021)

Validation of the A&D UM-212BLE monitor according to ISO 81060-2, 2018: a device with clinically important programmability
por: Alpert, Bruce S.
Publicado: (2023)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
por: Varano, Susann, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ncdqfuj2tgu09u808u65tphtq8